Related references
Note: Only part of the references are listed.Protective effects of aliskiren in doxorubicin-induced acute cardiomyopathy in rats
Azhar Rashikh et al.
HUMAN & EXPERIMENTAL TOXICOLOGY (2011)
Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity
Mohamed A. Ibrahim et al.
PHARMACOLOGICAL RESEARCH (2009)
Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats
Nagla A. El-Shitany et al.
FOOD AND CHEMICAL TOXICOLOGY (2008)
Dissociation of NEPH1 from nephrin is involved in development of a rat model of focal segmental glomerulosclerosis
Yasuhiro Otaki et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2008)
Differential effects of dihydropyridine calcium antagonists on doxorubicin-induced nephrotoxicity in rats
Li-Lin Liu et al.
TOXICOLOGY (2007)
The spectrum of podocytopathies: A unifying view of glomerular diseases
R. C. Wiggins
KIDNEY INTERNATIONAL (2007)
Salutary effect of pigment epithelium-derived factor in diabetic nephropathy - Evidence for antifibrogenic activities
Joshua J. Wang et al.
DIABETES (2006)
Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity
S Yilmaz et al.
TOXICOLOGY (2006)
Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients
AH Gradman et al.
CIRCULATION (2005)
Telmisartan is a promising cardiometabotic sartan due to its unique PPAR-gamma-inducing property
S Yamagishi et al.
MEDICAL HYPOTHESES (2005)
Estimation of podocyte number: A comparison of methods
KE White et al.
KIDNEY INTERNATIONAL (2004)
Cell biology of the glomerular podocyte
H Pavenstadt et al.
PHYSIOLOGICAL REVIEWS (2003)
Angiotensin II-receptor blockers: will they replace angiotensin-converting enzyme inhibitors in the treatment of hypertension?
NM Kaplan
JOURNAL OF HUMAN HYPERTENSION (2000)
Curcumin prevents adriamycin nephrotoxicity in rats
N Venkatesan et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)